Ignite Creation Date:
2024-05-06 @ 4:01 PM
Last Modification Date:
2024-10-26 @ 2:02 PM
Study NCT ID:
NCT04840004
Status:
RECRUITING
Last Update Posted:
2023-04-05
First Post:
2021-04-05
Brief Title:
Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer
Sponsor:
PlusVitech SL
Organization:
PlusVitech SL
Study Overview
Official Title:
Efficacy and Safety of PVT-1 Treatment in Patients With Advanced and Refractory Non-Small Cell Lung Cancer
Status:
RECRUITING
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Lung cancer is one of the most common causes of cancer death worldwide It is projected that the vast majority approximately 80 -85 of all lung cancer diagnosis is Non-Small Cell Lung Cancer NSCLC Although there are significant improvements in the treatment of Lung Cancer in recent years there is still an unmet medical need for a specific population which has advanced NSCLC and mostly is refractory to existing treatments
In NSCLC the molecular profile is important to direct the treatment Specifically for cases with an EGFR ALK ROS1 or PD1PDL1 molecular profile targeted treatments are available PVT-1 is a safe orally administrable and well-tolerated drug directed against a specific therapeutic target of cancer cells what has demonstrated efficacy in NSCLC with a molecular profile EGFR- ALK- ROS1- and refractory to anti-PD1 PDL1 in last line which also represents the highest percentage of patients and with the highest chances of cancer progression with currently available treatments
In NSCLC the molecular profile is important to direct the treatment Specifically for cases with an EGFR ALK ROS1 or PD1PDL1 molecular profile targeted treatments are available PVT-1 is a safe orally administrable and well-tolerated drug directed against a specific therapeutic target of cancer cells what has demonstrated efficacy in NSCLC with a molecular profile EGFR- ALK- ROS1- and refractory to anti-PD1 PDL1 in last line which also represents the highest percentage of patients and with the highest chances of cancer progression with currently available treatments
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None